Beneficial Effect of Sarpogrelate on Quality of Life in Patients with Peripheral Arterial Disease

Beneficial Effect of Sarpogrelate on Quality of Life in Patients with Peripheral Arterial Disease - Beneficial Effect of Sarpogrelate on Quality of Life in Patients with Peripheral Arterial Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008241

Enrollment

Registered

2012-06-24

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peripheral arterial disease

Interventions

300 mg of sarpogrelate per day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients having intermittent claudication with ABI less than 0.9

Exclusion criteria

Exclusion criteria: 1. patients with bleeding tendency 2. patients on maintenance hemodialysis 3. patients on cilostazol or beraprost sodium

Design outcomes

Primary

Measure	Time frame
VascuQOL	—

Secondary

Measure	Time frame
walking distance, WIQ, ABI, CAVI	—

Countries

Japan

Contacts

Public ContactAkihiro Hosaka

University of Tokyo Division of Vascular Surgery

hosaka-a@umin.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026